December, 02nd | 10:54 - 10:58
Efficacy and safety of mco-010 optogenetic therapy for vision restoration in patients with severe vision loss due to retinitis pigmentosa: 12-month results from a phase 2b, randomized, sham-controlled, multi-center, multi-dose, patient- and assessor-masked clinical trial (restore)
BANDELLO FRANCESCO
Full program
Add to calendar